Inna Gaydukova, EULAR 2021: Netakimab in Patients with Ankylosing Spondylitis with or without Sacroiliitis
It was a pleasure to meet with Professor Inna Gaydukova (North-Western State Medical University, St. Petersburg, Russia) to talk around the changes in ankylosing spondylitis activity in patients with and without sacroiliitis on netakimab treatment.
‘NETAKIMAB REDUCES ANKYLOSING SPONDYLITIS ACTIVITY IN PATIENTS WITH OR WITHOUT SACROILIITS ON MRI: RESULTS OF SUBANALYSIS OF PHASE 3 ASTERA TRIAL.‘ was presented at the European Congress of Rheumatology 2021, 2-5 June 2021.
- What did the Phase 3 ASTERA study teach us about the efficacy and safety of netakimab in patients with ankylosing spondylitis? (0:17)
- What are the clinical consequences of sacroiliitis in patients with ankylosing spondylitis? (1:31)
- Could you tell us a little about your recent sub analysis of the ASTERA trial data? (2:21)
- What are the wider implications of these findings? (4:02)
Disclosures: Inna Gaydukova has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of EULAR 2021 (Virtual).
Share this Video
Related Videos In Axial Spondyloarthritis
Xenofon Baraliakos, ACR 2022: Bimekizumab in the treatment of active non-radiographic axial spondyloarthritis and ankylosing spondylitis – 52 week findings from BE MOBILE 1 and 2
Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits both IL-17F and IL‑17A, was recently investigated in the phase 3 BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743) clinical trials for active non-radiographic axial spondyloarthritis and ankylosing spondylitis, respectively. touchIMMUNOLOGY were delighted to speak with Dr. Xenofon Baraliakos (Ruhr-Universität Bochum, Bochum, Nordrhein-Westfalen, Germany) to discuss […]
Sofia Ramiro, ACR 2022: Ixekizumab for radiographic axial spondyloarthritis – findings from the COAST-V trial
The COAST-V trial (NCT02696785) investigated the efficacy and safety of ixekizumab in patients with radiographic axial spondyloarthritis who were biological disease-modifying anti-rheumatic drug naïve. It was a pleasure to talk with Dr. Sofia Ramiro (Leiden University Medical Center, Leiden, Netherlands) to discuss the findings in terms of patient reported outcomes at weeks 16 and 52 […]
Xenofon Baraliakos, EULAR 2022: Bimekizumab in Patients with Active Non-Radiographic Axial Spondyloarthritis – BE MOBILE 1
BE MOBILE 1 (ClinicalTrials.gov Identifier: NCT03928704) is a a phase 3 study investigating bimekizumab in the treatment of active non-radiographic axial spondyloarthritis. touchIMMUNOLOGY were delighted to speak with Prof. Xenofon Baraliakos (Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany) around the aims of the BE MOBILE 1 study and the safety and efficacy findings. The abstract ‘Bimekizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!